Back to the fridge
Treatment

A fasting-style diet with chemo

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

de Groot S et al. · Nature Communications · 2020

The big question

In mice with tumors, short-term fasting protected against the toxic effects of chemotherapy and helped it work better. Could a diet that mimics fasting do the same for people with breast cancer?

What they did

Researchers randomly assigned 131 people with HER2-negative stage II or III breast cancer, who were getting chemotherapy before surgery, to a fasting mimicking diet (FMD) or their usual diet. The FMD lasted 4 days around each chemo dose: plant-based soups, broths, liquids and tea, about 1,200 calories on day 1 and about 200 calories on days 2 to 4. The FMD group did not get dexamethasone, a steroid usually given to ease side effects.

What they found

Side effects were similar in both groups, even without the steroid. Tumors shrank on scans more often with the FMD: about 3 times the odds of a partial or complete response. Among people who stuck to the diet, near-total loss of tumor cells (90 to 100%) had about 4 times the odds. The diet also reduced chemo-related DNA damage in immune cells.

Why it matters

These results encourage more research on fasting-style diets as a partner to chemotherapy.

What it doesn't mean

This was a mid-sized phase 2 trial. Sticking to the diet was hard: 81.5% finished the first cycle and just over half finished two. A larger planned trial did not go ahead. One author reported an equity stake in L-Nutra. Do not fast during treatment without your care team.

Read the original abstract
Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative stage II/III breast cancer, without diabetes and a BMI over 18 kg m−2, to receive either a fasting mimicking diet (FMD) or their regular diet for 3 days prior to and during neoadjuvant chemotherapy. Here we show that there was no difference in toxicity between both groups, despite the fact that dexamethasone was omitted in the FMD group. A radiologically complete or partial response occurs more often in patients using the FMD (OR 3.168, P = 0.039). Moreover, per-protocol analysis reveals that the Miller&Payne 4/5 pathological response, indicating 90-100% tumor-cell loss, is more likely to occur in patients using the FMD (OR 4.109, P = 0.016). Also, the FMD significantly curtails chemotherapy-induced DNA damage in T-lymphocytes. These positive findings encourage further exploration of the benefits of fasting/FMD in cancer therapy. Trial number: NCT02126449.

Abstract reproduced from de Groot S et al., Nature Communications (2020), under a CC BY 4.0 license, with punctuation lightly adapted. Plain-English summary by Womanhattan.

This summary was written with AI assistance and checked against the original paper. It is for learning, not medical advice. Talk with your care team before changing anything about your health or treatment.